دسته: آنتی بادیهای ایمونوهیستوشیمی
نمایش 521–530 از 530 نتیجه
فیلتر ها-
آنتی بادیهای ایمونوهیستوشیمی
آنتی بادی P40 کلون ZR8 برند Patho Sage
نمره 0 از 5Specification:
p63 consists of two major isoforms -TAp63 and ΔNp63. These isoforms differ in the structure of the N-terminal domains. The TAp63 isoform (identified by anti-p63 antibody) contains a transactivation- competent ‘TA’domain with homology to p53, which regulates the expression of the growth -inhibitor y genes. In contrast, ΔNp63 isoform (identified by anti-p40 antibody) contains an alternative transcriptionally- inactive ‘ΔN’ domain, which antagonizes the activity of TAp63 and p53. The p40 (clone ZR8) recognizes exclusively ΔNp63 but not TAp63. p40 is a squamous cell carcinoma ‘specific’ antibody. It reacts with the vast majority of cases of squamous cell carcinomas of various origins, but not with adenocarcinomas. It is particularly useful in differentiating lung squamous cell carcinoma from lung adenocarcinoma. p40 antibody can also be used as an alternative basal cell/myoepithelial cell marker, which has similar sensitivity and specificity as that of p63 antibody. Therefore, p40 antibody may also be used as an alternative immunohistochemical marker for determining prostate adenocarcinoma vs. benign prostate glands and for determining breast intraductal carcinoma v s. invasive breast ductal carcinoma.
Immunogen:
Synthesized polypeptides from N-terminal domain of p63
Presentation:
Purified antibody from in 0.2% BSA and 15mM sodium azide.
-
آنتی بادیهای ایمونوهیستوشیمی
آنتی بادی CD33 کلون PWS44 برند Patho Sage
نمره 0 از 5Specification:
CD33 (gp67, or siglec-3) is a 67 kDa glycosylated transmembrane protein that is a member of the sialic acid–binding immunoglobulin-like lectin (siglec) family. The genomic locus of this protein has been mapped to chromosome 19q13.1-3.5. In maturing granulocytic cells, there is progressive downregulation of CD33 from the blast stage to mature neutrophils. However, in monocytes and macrophages/histiocytes, strong expression of CD33 is maintained throughout maturation. Therefore, the positive control tissue should be bone marrow myeloid cells (especially myeloid precursors), liver Kupffer cells, lung alveolar macrophages, or placental syncytiotrophoblasts. Detection of CD33 using monoclonal antibodies has been a critical component in immunophenotyping acute leukemias, particularly acute myeloid leukemias. This anti-CD33 may be particularly advantageous for cases of acute myeloid leukemia, minimally differentiated (AML-M0) and acute monocytic leukemia (AML-M5), in which other paraffin section markers of myeloid differentiation (such as antimyeloperoxidase) may be negative. However, anti-CD33 staining cannot be used in isolation and must be correlated with other myeloid and lymphoid markers because cases of myeloid antigen–positive acute lymphoblastic leukemia may show bona fide CD33 expression.
Presentation:
Antibody diluted in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
-
آنتی بادیهای ایمونوهیستوشیمی
آنتی بادی ATRX کلون Polyclonal برند Patho Sage
نمره 0 از 5Specification:
Defects in alpha thalassemia/mental retardation syndrome X-linked (ATRX), a gene that encodes a protein involved in chromatin remodeling. ATRX mutation is a marker of astrocytic lineage among the IDH1-mutant gliomas and is mutually exclusive with 1p/19q codeletion. ATRX mutations are most frequently in grade II (67%) and grade III (73%) astrocytomas and secondary glioblastoma multiforme (GBM) (75%), whereas they are uncommon in primary GBMs and oligodendrogliomas. Nearly all diffuse gliomas with IDH and ATRXmutations also harbor TP53 mutation and are associated with the alternative lengthening of telomeres (ALT) phenotype. ATRX mutation also occurs in many other types of human tumors, such as neuroendocrine tumors. Immunohistochemistry for ATRX demonstrates a loss of protein expression in neoplastic cells that harbor inactivating mutations, whereas expression is retained in nonneoplastic cells within the sample, such as endothelial cells.
Immunogen:
Synthetic peptide from human ATRX protein
Presentation:
Purified antibody fraction from rabbit anti-serum with 0.2% BSA and 15mM sodium azide
-
آنتی بادیهای ایمونوهیستوشیمی
آنتی بادی Oct3/4 کلون C-10 برند Patho Sage
نمره 0 از 5Specification:
Transcription factors containing the POU homeo domain have been shown to be important regulators of tissue-specific gene expression in lymphoid and pituitary differentiation and in early mammalian development. POU domain proteins contain a bipartite DNA-binding domain divided by a flexible linker that enables them to adopt various monomer configurations on DNA. The versatility of POU protein operation is additionally conferred at the dimerization level. Oct-3 (also known as Oct-4) is a mammalian POU transcription factor expressed by early embryo cells and germ cells. Oct-3/4 is essential for the identity of the pluripotential founder cell population in the mammalian embryo. A critical amount of Oct3/4 is required to sustain stem-cell self renewal, and up or down regulation induce divergent developmental programs. Two isoforms of Oct-3,termed Oct-3A and Oct-3B, are generated by alternative splicing. The gene which encodes Oct-3/4 maps to human chromosome 6p21.3. Oct-3/4 (C-10) is recommended for detection of Oct-3A (Oct-4) and Oct-3B of mouse, rat and human origin by Western Blotting, immunoprecipitation, immunofluorescence, and paraffin immunohistochemistry.
Immunogen:
Amino acids1-134 of Oct-3/4 of human origin
Presentation:
Purified antibody in 0.2 % BSA and 15mM sodium azide
-
آنتی بادیهای ایمونوهیستوشیمی
آنتی بادی GFAP کلون EP672Y برند Patho Sage
نمره 0 از 5Specification:
Anti-GFAP antibody detects astrocytes, Schwann cells, satellite cells, enteric glial cells and some groups of ependymal cells. This marker is mainly used to distinguish neoplasms of astrocytic origin from other neoplasms in the central nervous system.
Presentation:
Anti-GFAP is a rabbit monoclonal from tissue culture supernatant diluted in tris buffered saline, pH 7.3-7.7, with protein base, and preserved with sodium azide
-
آنتی بادیهای ایمونوهیستوشیمی
آنتی بادی GFAP کلون GA5 برند Patho Sage
نمره 0 از 5Specification:
This antibody recognizes a protein of ~50kDa which is identified as Glial Fibrillary Acidic Protein (GFAP, also known as Astrocyte or Intermediate Filament Protein). It shows no cross-reaction with other intermediate filament proteins. GFAP is specifically found in astroglia. GFAP is a very popular marker for localizing benign astrocyte and neoplastic cells of glial origin in the central nervous system.
Immunogen:
GFAP isolated from pig spinal cord
Presentation:
Bioreactor Concentrate with 0.05% Azide
-
آنتی بادیهای ایمونوهیستوشیمی
آنتی بادی SOX11 کلون ILQ158 برند Patho Sage
نمره 0 از 5Specification:
Mantle cell lymphoma (MCL) accounts for 5% to 10% of mature B-cell neoplasms and is an aggressive disease genetically characterized by overexpression of cyclin D1 (CCND1) due to the specific translocation t(11;14) (q13;q32)1. It is necessary that MCL be distinguished from potential morphologic mimics, including chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL), follicular lymphoma (FL), and marginal zone lymphoma (MZL) based on immunohistochemical (IHC) staining for CD5, CD23, and CD101. MCL and CLL both express CD5 but MCL, in contrast to CLL, generally lacks CD23 expression by IHC. FL lacks expression of both CD5 and CD23 but most often expresses CD10, whereas MZL is typically negative for all 3 antigens1. Cyclin D1 overexpression is thus the hallmark of MCL even though approximately 5%-10% of MCLs lack Cyclin D1 expression and may be misdiagnosed by overreliance on CyclinD1 IHC2-3. The recognition of cyclin D1negative MCL is difficult because it may resemble other small B-cell lymphomas morphologically and phenotypically4. Although the clinical information on cyclin D1-negative MCL is limited, published data indicate that the behavior of the variant is as aggressive as that of conventional MCL4,5. On the other hand, patients with small B-cell lymphomas mimicking MCL have a significantly better outcome than those with true MCL. It is, therefore, important to find reliable biomarkers that may allow the identification of cyclin D1-negative MCL in clinical practice.
SOX-11, the SRY (sex-determining region Y)-box11 gene, a transcription factor, normally is expressed in the developing human central nervous system6, medulloblastoma7, and glioma8. In a series study4, SOX- 11 expression was investigated in 54 cyclin D1-positive MCL and 209 other lymphoid neoplasms. Interestingly, nearly all MCL were strongly positive for antiSOX-11 (50/54, 93%), with a nuclear pattern. The staining was intense and relatively homogeneous in most of the cells.
Compared to anti-cyclin D1 staining, anti-SOX-11 reactivity was stronger and more homogeneous. Five T-cell and B-cell lymphoblastic leukemia/lymphomas showed strong SOX-11 nuclear expression. One case of classic Hodgkin lymphoma, two of eight BL and two of three T-cell prolymphocytic leukemias were also positive. SOX-11 protein expression was examined by immunohistochemistry in the 12 cyclin D1-negative MCL, and all of them showed strong nuclear positive staining similar to that occurring in conventional cyclin D1-positive MCL4. The expression of SOX-11 in reactive tonsil, lymph node and spleen specimens was studied4. No nuclear expression was observed in any lymphocyte compartment4. Only cytoplasmic staining was seen in cells from reactive germinal centers. Zeng et al.9 has evaluated SOX- 11 expression by immunohistochemistry in 140 cases of mature B-cell neoplasms, including 4 cases of suspected blastoid MCL that lacked cyclin D1 expression and 8 cases of CD5-positive diffuse large B-cell lymphoma (DLBCL). Nuclear expression of SOX-11 was found in cyclin D1-positive MCL (30/30, 100%) and in a case of cyclin D1-negative MCL with typical morphology. SOX-11 was expressed in Burkitt lymphoma (1/5, 20%) and lymphoblastic lymphoma (2/3 T-LBLs, 2/2 B-LBLs, overall 4/5, 80%), whereas all cases of DLBCL (including CD5-positive DLBCL) and other small B-cell neoplasms were negative. The 4 suspected cases of blastoid MCL were also anti-SOX-11-positive. These cases had a complex karyotype that included 12p abnormalities.
Therefore, the authors confirmed prior reports that SOX-11 nuclear expression was a specific marker for MCL, including cyclin D1-negative MCL with typical morphology. Their study indicates that SOX-11 IHC is of value in further defining pathologic features of CD5+ DLBCL. Routine use of anti-SOX-11 in cases of suspected CD5+ DLBCL might help identify additional cases of cyclin D1-negative blastoid MCL.
In summary, nuclear protein expression of SOX-11 is highly associated with both cyclin D1-positve and negative MCL. The detection of this transcription factor is a useful biomarker for identifying true cyclin D1- negative MCL. SOX-11 IHC is of value in further defining pathologic features of CD5+ DLBCL. Routine use of anti-SOX-11 in cases of suspected CD5+ DLBCL might help identify additional cases of cyclin D1-negative blastoid MCL. SOX-11 can also be detected in some BL, LBL and TPLL, although the different morphological and phenotypic features of these malignancies allow easy recognition of the cases of cyclin D1-negative MCL.
Presentation:
This antibody is diluted in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
-
آنتی بادیهای ایمونوهیستوشیمی
آنتی بادی MITF (Microphthalmia-Associated Transcription Factor) کلون 34CA5 برند Patho Sage
نمره 0 از 5Specification:
Microphthalmia transcription factor (MITF) gene product, a nuclear transcription factor of the basic-helix-loop-helix type, is thought to play a role in the regulation of genes encoding the enzymes necessary for melanogenesis. These include tyrosinase, TRP-1 and TRP-2. MITF is critical for the embryonic development and postnatal viability of melanocytes.
Immunogen:
Prokaryotic recombinant protein corresponding to 111 amino acids of the N-terminal region of the MITF-M molecule
Presentation:
Liquid tissue culture supernatant containing 15mM sodium azide
-
آنتی بادیهای ایمونوهیستوشیمی
آنتی بادی NUT1 کلون C52B1 برند Patho Sage
نمره 0 از 5Specification:
Nuclear protein in testis (NUT) is normally confined to the germ cells of the testis and ovary (1,2). NUT midline carcinoma (NMC) is a recently recognized cancer that is defined by the presence of chromosomal rearrangements involving the NUT gene on chromosome 15q14 (3). In most cases the chromosomal translocation occurs between NUT and BRD4 on chromosome 19, resulting in the formation of a BRD4-NUT fusion protein. In the remaining tumours, variant NUT rearrangements are present involving BRD3, a very close homolog of BRD4. BRD4-NUT and BRD3-NUT encode fusion proteins that appear to contribute to carcinogenesis by blocking epithelial cell differentiation. NMCs, which are aggressive and highly lethal carcinomas, are morphologically indistinguishable from other poorly differentiated carcinomas. Given the limited expression of endogenous NUT protein, this antibody can be used to detect NUT fusion proteins in tissues by immunohistochemistry and immunofluorescence (2). NUT (C52B1) Rabbit mAb detects endogenous levels of total NUT protein. The antibody also detects endogenous levels of the BRD4-NUT fusion protein found in NUT midline carcinoma (NMC).
Immunogen:
Recombinant protein corresponding to the human NUT protein
Presentation:
Supplied in 10 mM HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA, 50% glycerol and less than 0.02% sodium azide
-
آنتی بادیهای ایمونوهیستوشیمی
آنتی بادی CD19 کلون LE-CD19 برند Patho Sage
نمره 0 از 5Specification:
LE-CD 19 recognizes CD19, a 95 kD cell surface glycoprotein, which is expressed by cells of the B cell lineage and follicular dendritic cells. CD 19 is absent on plasma cells. CD 19 is an important signal transduction molecule which is involved in the regulation of B lymphocyte development, activation and differentiation. LE-CD 19 detects a band of approximately 95 kDa in Raji cell lysates under reduction conditions.
Immunogen:
CD19 peptide CGPDPAWGGGGRMGTWSTR (C-terminus) coupled to KLH
Presentation:
purified IgG prepared by affinity chromatography at 200µg/ml in PBS, pH with BSA and Sodium Azide